Innovent expands Phase 3 MarsLight-11 NSCLC study to include non-squamous NSCLC

Innovent Biologics announced that its global Phase 3 MarsLight-11 trial of IBI363/TAK-928, an experimental alpha-biased IL-2/PD-1 bispecific fusion protein, will expand to include patients with non-squamous non-small cell lung cancer (NSCLC). The expansion aims to broaden access to the study for patients whose disease progressed after chemotherapy and prior immunotherapy, and it reflects ongoing efforts to test new immunotherapy combinations in diverse NSCLC subtypes.

What changed in the trial

The MarsLight-11 study, already testing IBI363/TAK-928 in squamous NSCLC, will add a substudy for non-squamous NSCLC. In practice, this means the same experimental therapy will be evaluated in a broader group of patients whose cancer is a different NSCLC subtype. The study is global, multicenter, randomized, and controlled, which are standard features of late-stage clinical trials intended to show whether a treatment improves outcomes compared with existing options.

Key facts about the therapy and the disease context

IBI363/TAK-928 is described as a bispecific fusion protein that combines mechanisms targeting an alpha-biased IL-2 pathway and PD-1. In simple terms, it is designed to stimulate the immune system to fight cancer while potentially modulating immune checkpoints. NSCLC stands for non-small cell lung cancer, the most common type of lung cancer. Non-squamous NSCLC is a subtype that can have different biology and treatment responses from squamous NSCLC. The trial focuses on patients whose disease did not respond to prior chemotherapy and prior immunotherapy, a group often termed immunotherapy-resistant.

Who is affected by the expansion

The expansion specifically affects adults with non-squamous NSCLC whose disease has progressed after standard treatments, and who are eligible for participation in a Phase 3 trial. If you are a patient, clinician, or caregiver, the expansion may influence access to a trial option in addition to approved therapies, depending on regional availability and trial enrollment status. The announcement notes a global, multicenter approach, implying multiple sites may offer the substudy.

Practical next steps for patients and clinicians

For patients or clinicians interested in trial participation, the typical steps include confirming eligibility for the MarsLight-11 protocol and the non-squamous substudy, discussing potential risks and benefits with the trial team. Checking enrollment status at trial sites. Trial participation usually involves specified inclusion criteria, regular monitoring, and visits to study centers for assessments. Potential participants should consult their oncology care team to determine fit and to receive up-to-date information on site availability, consent forms, and timelines.

Limits of the information and open questions

The source provides a press-release summary of the trial expansion but does not include detailed data on expected efficacy, safety profiles, or enrollment numbers. Readers should consider that early reports about trials describe planned activities rather than proven results. Important questions include how the non-squamous substudy might affect overall trial outcomes, the exact endpoints to be measured, and whether regulatory approvals or regional access could be influenced by this expansion.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.